The National Eye Institute’s Ophthalmic Genetics and Visual Function Branch seeks partners to co-develop the protocol for iPSC to RPE differentiation and its use in clinical, screening and translational settings.
The National Cancer Institute seek parties interested in in-licensing and/or collaborative research to develop and commercialize cell labeling, cell tracking, cell trafficking, cell-based therapy, and PET imaging for cancer.
NIH scientists created and characterized an excellent mouse model for TNBC that shares important molecular characteristics of human TNBC making it highly useful for preclinical testing of drugs and novel therapies. This model may provide a valuable means of identifying new drugs and therapies that could be translated to human clinical trials.The NCI seeks parties interested in licensing this mouse model of prostate and triple-negative breast cancers to study cancer biology and for preclinical testing.
The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Section on Molecular Neurobiology seeks parties interested in licensing or collaborative research to further evaluate or commercialize specific rabbit monoclonal antibodies generated against the ErbB4 receptor (also known as HER4) that have been validated for specificity using tissue sections and extracts from ErbB4 knockout mice.
The National Cancer Institute seeks licensees or research collaborators to develop and commercialize transgenic mice having immunocompetent rat growth hormone-firefly Luciferase-enhanced green fluorescent protein.
Researchers at the National Cancer Institute, Laboratory of Cancer Biology and Genetics believe that a better understanding of GATA-3 function and dysregulated during the onset and progression of breast cancer will lead to new strategies in diagnosing and treating the disease.
The Surgery Branch of the National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to carry out genotypic as well as phenotypic analysis of the 888 mel cell line in order to better understand the nature of tumor cells that respond to therapy.
The National Institute of Child Health and Human Development (NICHD), Division of Intramural Research, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize clinical samples with genetic mutations associated with endocrine tumors.
The National Cancer Institute Cancer Genetics Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize mouse epithelial cancer cell lines.
NCI's Center for Advanced Preclinical Research (CAPR) has developed a Serous Epithelial Ovarian Cancer (SEOC) genetically engineered mouse model (GEM), GEM-derived SEOC orthotopic mouse model, and biological materials derived therefrom, with several key histopathologic, immunophenotypical, and genetic features of human SEOC. NCI CAPR seeks licensees for this technology.
The National Cancer Institute seeks licensees for a model used to study molecular mechanisms and/or signaling pathways involved in tumorigenesis, angiogenesis and metastasis of breast cancer and its response to therapy.